BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06), Zacks reports. The business had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. The firm's revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the business earned $0.28 earnings per share.
BioCryst Pharmaceuticals Price Performance
BioCryst Pharmaceuticals stock traded up $0.11 during trading hours on Thursday, hitting $8.47. The company had a trading volume of 4,430,582 shares, compared to its average volume of 3,060,151. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $9.50. The firm has a market cap of $1.75 billion, a PE ratio of -13.89 and a beta of 1.75. The firm has a 50-day moving average of $8.09 and a 200 day moving average of $7.85.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on BCRX. Royal Bank of Canada restated an "outperform" rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday. Evercore ISI boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday. They issued an "outperform" rating and a $15.00 target price on the stock. Barclays lifted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 5th. Finally, Needham & Company LLC upped their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $15.57.
Get Our Latest Report on BioCryst Pharmaceuticals
About BioCryst Pharmaceuticals
(
Get Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Featured Stories
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
